AspyreRx ma.1.0.0
AspyreRx ma.1.0.0 is a mental health/function therapeutic software (FDA Class II; FDA product code QXC, Diabetes Digital Therapeutic Device) made by Better Therapeutics, granted FDA De Novo DEN220058 on 7 Jul 2023 and listed in FDA GUDID since 16 Oct 2023 (UDI-DI 00860011146704), active as of 22 Oct 2026.
Active
De Novo
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | GUDID listing | Number00860011146704 | Date16 Oct 2023 | StatusListed |
| United States | FDA De NovoDENG | NumberDEN220058 | Date7 Jul 2023 | StatusActive |
Official records
- AccessGUDID record 00860011146704
- FDA De Novo database DEN220058
From the FDA record
- Device description
- BT-001 (AspyreRx) is a prescription-only digital therapeutic device intended to provide cognitive behavioral therapy to treat patients 18 years or older with type 2 diabetes.
- MRI safety
- Labeling does not contain MRI Safety Information
- Natural rubber latex
- No latex statement on the label
- Sterility
- Supplied non-sterile
Across registries
- FDA De Novo DEN220058 decided 7 Jul 2023 Active
- FDA GUDID UDI-DI 00860011146704 listed 16 Oct 2023 Listed
Timeline
- Granted FDA De Novo DEN220058
- Listed FDA GUDID 00860011146704
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA De Novo Active
Specification
- Trade name
- AspyreRx
- Generic name
- Mental health/function therapeutic software, screen-viewed
- Model / reference
- ma.1.0.0
- Primary DI / UDI-DI
- 00860011146704
- De Novo Number
- FDA product code
- QXC
- GMDN term
- Mental health/function therapeutic software, screen-viewed
- Device class
- Class II
- Regulation number
- 880.5735
- GUDID distribution status
- In Commercial Distribution